20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters
Jan P. Deroose(Cancer Clinic), Cornelis Verhoef(Erasmus MC Cancer Institute), Albertus N. van Geel, Jacobus W. A. Burger(Radboud University Nijmegen), Alexander M.M. Eggermont(University Medical Center Utrecht), Johannes H. W. de Wilt(Radboud University Nijmegen)
Cited by 74
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k